On September 7, 2021 BeyondSpring Inc. ("BeyondSpring") (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, reported that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time (Press release, BeyondSpring Pharmaceuticals, SEP 7, 2021, View Source;utm_medium=rss&utm_campaign=beyondspring-to-host-second-quarter-financial-results-and-corporate-update-conference-call-on-september-10-2021 [SID1234587329]). Details for the conference call are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Friday, September 10 @ 8:00 AM Eastern Time
Domestic: 877-451-6152
International: 201-389-0879
Conference ID: 13722968
Webcast: View Source
An archived replay of the webcast will be available for 90 days on BeyondSpring’s website at www.beyondspringpharma.com under "Events & Presentations" in the Investors section.

On September 7, 2021 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that the Company will present at three upcoming virtual investor conferences in September (Press release, Marker Therapeutics, SEP 7, 2021, View Source [SID1234587345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

H.C. Wainwright Annual Global Investment Conference
Company Presenter: Anthony H. Kim, Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Company Presenter: Mythili Koneru, M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22, 2021
Time: 9:05 a.m. ET

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET

Live webcasts of the presentations will be accessible from the Investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

On September 7, 2021 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23RD Annual Global Life Sciences Conference taking place September 13-15, 2021 (Press release, Neoleukin Therapeutics, SEP 7, 2021, View Source [SID1234587361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation will be available for on-demand access beginning at 7:00 am ET on Monday, September 13, 2021 from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.

On September 7, 2021 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. PT on Monday, September 13, 2021 (Press release, Sana Biotechnology, SEP 7, 2021, View Source [SID1234587297]). The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.

On September 7, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 (Press release, Akari Therapeutics, SEP 7, 2021, https://www.akaritx.com/2021/09/07/akari-therapeutics-to-present-at-the-h-c-wainwright-global-investment-conference/ [SID1234587314]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the Company’s presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. ET by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event.